杨爽, 王力宁. 影响他克莫司浓度的药物遗传学研究进展[J]. 临床肾脏病杂志, 2020, 20(9): 752-757. DOI: 10.3969/j.issn.1671-2390.2020.09.013
    引用本文: 杨爽, 王力宁. 影响他克莫司浓度的药物遗传学研究进展[J]. 临床肾脏病杂志, 2020, 20(9): 752-757. DOI: 10.3969/j.issn.1671-2390.2020.09.013
    YANG Shuang, WANG Li-ning. Progress in pharmacogenetic studies on effect on tacrolimus concentrations[J]. Journal of Clinical Nephrology, 2020, 20(9): 752-757. DOI: 10.3969/j.issn.1671-2390.2020.09.013
    Citation: YANG Shuang, WANG Li-ning. Progress in pharmacogenetic studies on effect on tacrolimus concentrations[J]. Journal of Clinical Nephrology, 2020, 20(9): 752-757. DOI: 10.3969/j.issn.1671-2390.2020.09.013

    影响他克莫司浓度的药物遗传学研究进展

    Progress in pharmacogenetic studies on effect on tacrolimus concentrations

    • 摘要: 他克莫司药代动力学及药效动力学参数代谢个体差异大,治疗窗窄,是导致排斥或毒性反应的主要原因,其中遗传因素是引起他克莫司代谢个体差异的主要原因之一。本文就影响他克莫司血药浓度的遗传因素(主要包括代谢酶基因多态性及药物转运蛋白基因多态性)进行综述,从而为临床实现他克莫司个体化治疗提供参考。

       

      Abstract: The pharmacokinetic and pharmacodynamic parameters of tacrolimus have big individual differences,and the drug has a narrow treatment window.These are main causes leading to rejection and toxic reactions,and hereditary factors are one of main causes for individual difference of tacrolimus efficacy.In this paper,we review the hereditary factors which affect tacrolimus concentrations,mainly including metabolic enzyme gene polymorphism and dry delivery protein gene polymorphism,so as to provide reference for achievement of clinical individualized treatment with tacrolimus.

       

    /

    返回文章
    返回